Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review

Sunaina Banu; Lakshmi Puzhankara; Madhurya N Kedlaya; Jothi M Varghese; Venkitachalam Ramanarayanan

doi:10.7126/cumudj.1110413

EN

Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review

Abstract

Objectives The use of Sclerostin Antibody(Scl-Ab) as a bone anabolic agent has shown significant benefit in bone disorders in preclinical animal models and human clinical trials. Currently available evidence on the use of Scl-Ab in alveolar bone regeneration is limited to animal studies and hence this scoping review encompasses the animal studies conducted to ascertain the effectiveness of Scl-Ab on alveolar bone regeneration. Materials and methods The search strategy was aimed to locate published animal studies in which the treatment arm includes Sclerostin antibody administration for alveolar bone preservation or regeneration. The search terms used were (((Animal model) OR Rodent) AND Alveolar bone defect) AND Anti sclerostin antibody) OR Sclerostin antibody) AND Alveolar bone regeneration) OR Bone regeneration) AND Bone fill. Results Of the 559 results from Medline/PubMed, Scopus, Web of Science, Google scholar and additional articles from the references, six were included in the review. Scl-Ab was found to be effective in improving the bone quality and quantity. It was also observed that Scl-Ab was useful in reduced bone density associated with diseases and conditiona affecting osteoblast activity. Conclusion The review concluded that Scl-Ab promotes alveolar bone augmentation and improves bone quality without surgical interventions.

Keywords

References

1. Könönen E, Gursoy M, Gursoy UK. Periodontitis: A Multifaceted Disease of Tooth-Supporting Tissues. J Clin Med. 2019;8(8):1135. doi:10.3390/JCM8081135
2. Cekici A, Kantarci A, Hasturk H, Dyke TE Van. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000. 2014;64(1):57. doi:10.1111/PRD.12002
3. Bansal P, Singh P, Bey A, Gupta ND. Sclerostin and occlusion: A brief review. J Indian Soc Periodontol. 2015;19(1):11. doi:10.4103/0972-124X.145785
4. Ten Dijke P, Krause C, de Gorter DJ, Löwik CW, van Bezooijen RL. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008;90 Suppl 1(SUPPL. 1):31-35. doi:10.2106/JBJS.G.01183
5. van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199(6):805-814. doi:10.1084/JEM.20031454
6. Balemans W, Cleiren E, Siebers U, Horst J, Van Hul W. A generalized skeletal hyperostosis in two siblings caused by a novel mutation in the SOST gene. Bone. 2005;36(6):943-947. doi:10.1016/J.BONE.2005.02.019
7. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet. 2001;10(5):537-543.
8. Brunkow ME, Gardner JC, Van Ness J, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577-589. doi:10.1086/318811

9. Loots GG, Kneissel M, Keller H, et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 2005;15(7):928-935. doi:10.1101/GR.3437105
10. Li X, Warmington KS, Niu QT, et al. Inhibition of sclerostin by monoclonal antibody increases bone formation, bone mass, and bone strength in aged male rats. J Bone Miner Res. 2010;25(12):2647-2656. doi:10.1002/JBMR.182
11. Li X, Ominsky MS, Warmington KS, et al. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. Endocrinology. 2011;152(9):3312-3322. doi:10.1210/EN.2011-0252
12. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res. 2009;24(4):578-588. doi:10.1359/JBMR.081206
13. Ominsky MS, Boyce RW, Li X, Ke HZ. Effects of sclerostin antibodies in animal models of osteoporosis. Bone. 2017;96:63-75. doi:10.1016/J.BONE.2016.10.019
14. Axelrad TW, Kakar S, Einhorn TA. New technologies for the enhancement of skeletal repair. Injury. 2007;38 Suppl 1(SUPPL. 1). doi:10.1016/J.INJURY.2007.02.010
15. Tricco AC, Lillie E, Zarin W, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-473. doi:10.7326/M18-0850
16. Yu SH, Hao J, Fretwurst T, et al. Sclerostin-Neutralizing Antibody Enhances Bone Regeneration Around Oral Implants. Tissue Eng - Part A. 2018;24(21-22):1672-1679. doi:10.1089/ten.tea.2018.0013
17. Witcher PC, Miner SE, Horan DJ, et al. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI insight. 2018;3(11). doi:10.1172/jci.insight.98673
18. Heiland GR, Zwerina K, Baum W, et al. Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression. Ann Rheum Dis. 2010;69(12):2152-2159. doi:10.1136/ard.2010.132852
19. Yao Y, Kauffmann F, Maekawa S, et al. Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects. Sci Rep. 2020;10(1):1-10. doi:10.1038/s41598-020-73026-y
20. Liu M, Kurimoto P, Zhang J, et al. Sclerostin and DKK1 Inhibition Preserves and Augments Alveolar Bone Volume and Architecture in Rats with Alveolar Bone Loss. J Dent Res. 2018;97(9):1031-1038. doi:10.1177/0022034518766874
21. Chen H, Xu X, Liu M, et al. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 2015;76:141-148. doi:10.1016/j.bone.2015.04.002
22. Taut AD, Jin Q, Chung JH, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013;28(11):2347-2356. doi:10.1002/jbmr.1984
23. Ren Y, Han X, Ho SP, et al. Removal of SOST or blocking its product sclerostin rescues defects in the periodontitis mouse model. FASEB J. 2015;29(7):2702-2711. doi:10.1096/fj.14-265496
24. Tamplen M, Fowler T, Markey J, Knott PD, Suva LJ, Alliston T. Treatment with anti-Sclerostin antibody to stimulate mandibular bone formation. Head Neck. 2018;40(7):1453-1460. doi:10.1002/hed.25128
25. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1). doi:10.1186/1471-2288-14-43
26. Zhang D, Hu M, Chu T, et al. Sclerostin antibody prevented progressive bone loss in combined ovariectomized and concurrent functional disuse. Bone. 2016;87:161-168. doi:10.1016/j.bone.2016.02.005
27. Stolina M, Dwyer D, Niu QT, et al. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats. Bone. 2014;67:305-313. doi:10.1016/j.bone.2014.07.031
28. McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412-420. https://europepmc.org/article/med/24382002. Accessed May 27, 2021.
29. Allison H, Holdsworth G, McNamara LM. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes. BMC Mol Cell Biol. 2020;21(1). doi:10.1186/s12860-020-00322-w
30. Pinzone JJ, Hall BM, Thudi NK, et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood. 2009;113(3):517-525. doi:10.1182/blood-2008-03-145169
31. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev. 1997;28(1):5-24. doi:10.1016/S0169-409X(97)00048-3
32. Bouaziz W, Funck-Brentano T, Lin H, et al. Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways. Arthritis Res Ther. 2015;17(1):24. doi:10.1186/s13075-015-0540-6
33. Wehmeyer C, Frank S, Beckmann D, et al. Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction. Sci Transl Med. 2016;8(330). doi:10.1126/scitranslmed.aac4351

Details

Primary Language

English

Subjects

Health Care Administration

Journal Section

Review

Authors

Sunaina Banu
0000-0002-6893-4630
India

Lakshmi Puzhankara ^*
0000-0002-5559-5887
India

Madhurya N Kedlaya
0000-0003-2888-3274
India

Jothi M Varghese
0000-0002-8503-5039
India

Venkitachalam Ramanarayanan
0000-0002-5587-3453
India

Publication Date

December 30, 2022

Submission Date

May 10, 2022

Acceptance Date

December 22, 2022

Published in Issue

Year 2022 Volume: 25 Number: 4

DOI

https://doi.org/10.7126/cumudj.1110413

IZ

https://izlik.org/JA78GX24WU

Cite

RIS / Bibtex

EndNote

Banu S, Puzhankara L, Kedlaya MN, Varghese JM, Ramanarayanan V (December 1, 2022) Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review. Cumhuriyet Dental Journal 25 4 341–349.

Öz

Is sclerostin antibody an effective agent for alveolar bone regeneration in animal models? A scoping review

Abstract

Keywords

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite